Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin’s diffuse large B-cell lymphoma

Jm, Cervera Grau; G, Esquerdo Galiana; A, Belso Candela; C, Llorca Ferrándiz; A, Juárez Marroquí; S, Maciá Escalante

doi:10.1007/s12094-008-0201-1

Cited by 14 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whether rituximab causes cardiomyopathy is controversial [13–16]. We analyzed the 10 patients who developed cardiomyopathy after receiving rituximab in more details (see Table 3).…”

Section: Resultsmentioning

confidence: 99%

Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors

et al. 2017

View full text Add to dashboard Cite

Our aim is to study unanticipated cardiotoxicity associated with the use of anticancer targeted agents, a problem that remains poorly understood. Using diagnosis codes, we retrospectively identified patients with both hematologic malignancies (HM) and cardiovascular diseases (n = 820 patients). Cardiotoxicity was defined per published criteria. The targeted agents of interest included tyrosine kinase inhibitors, proteasome inhibitors, monoclonal antibodies, and immunomodulatory agents. Patients found with cardiotoxicity (n = 29) were compared with 70 case-matched reference subjects. Median time from targeted therapy exposure to cardiotoxicity was 132 days. A higher percentage of patients had prior exposure to anthracyclines in study versus reference group (65.5 vs. 42.8%, P = 0.04), however, did not stay significant in multivariate analysis. Two variables were significant predictors, prior of DVT/PE and Karnofsky score of ≥ 80% (P ≤ 0.011). Only 2 study group patients died of cardiac causes. Most cardiotoxicity patients (23/29) had remained stable or improved, while 21 patients received further chemotherapy. OS was lower in the study group (P = 0.018) versus the reference group. In conclusion, a small number patients with HM experience unanticipated cardiotoxicity with low related mortality. Risk of cardiotoxicity was significantly associated with history of DVT/PE. Most patients do well, but despite that, their OS is significantly poorer.

show abstract

“…Whether rituximab causes cardiomyopathy is controversial [13–16]. We analyzed the 10 patients who developed cardiomyopathy after receiving rituximab in more details (see Table 3).…”

Section: Resultsmentioning

confidence: 99%

Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Infusion reactions associated with Rituximab therapy have been reported including cardiac arrhythmia such as monomorphic ventricular tachycardia, supraventricular tachycardia, trigeminy, and irregular pulse [ 2 – 4 ]. Moreover, it can also cause bradycardia and AV blocks [ 2 , 5 , 6 ]. Based on our knowledge, this is the second case report of Rituximab causing high grade AV block as there has only been one case report of complete AV block after the fifth dose of Rituximab [ 5 ].…”

Section: Discussionmentioning

confidence: 99%

A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma

Minaskeian

Masry

2020

Cardio-Oncology

View full text Add to dashboard Cite

This is a case of a middle-aged woman with underlying cardiac conduction system with episodes of AV Wenckebach, who subsequently developed significant AV conduction system abnormalities after receiving one standard dose of Rituximab infusion for diffuse large B-cell lymphoma. Rituximab, being a monoclonal antibody against CD-20 antigen, is effective in treatment of B-cell lymphoma but may also cause bradyarrythmias likely due to the calcium ion channel property of CD-20 antigen.

show abstract

“…[ 9 ] Complete atrioventricular block induced by rituximab monotherapy in an 83-year-old has also been described in literature. [ 10 ] Another recent report of polymorphic ventricular tachycardia causing syncope during initial infusion of rituximab raises concerns of arrhythmogenic side effects of this medication. [ 11 ] Despite these reports a study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function concluded with confirmation of lack of cardiotoxic effect of a fast infusion rate.…”

Section: Discussionmentioning

confidence: 99%

Rituximab Induced Left Bundle Branch Block

2015

View full text Add to dashboard Cite

show abstract

Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin’s diffuse large B-cell lymphoma

Cited by 14 publications

References 6 publications

Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors

Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors

A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma

Rituximab Induced Left Bundle Branch Block

Contact Info

Product

Resources

About